Abbott Laboratories (NYSE:ABT) Holdings Lifted by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC raised its position in shares of Abbott Laboratories (NYSE:ABT) by 0.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 198,237 shares of the healthcare product maker’s stock after acquiring an additional 874 shares during the period. Abbott Laboratories makes up 2.4% of Marble Harbor Investment Counsel LLC’s portfolio, making the stock its 10th biggest position. Marble Harbor Investment Counsel LLC’s holdings in Abbott Laboratories were worth $20,599,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ABT. Unique Wealth Strategies LLC purchased a new position in Abbott Laboratories in the second quarter valued at approximately $28,000. Redmont Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at $30,000. Richardson Financial Services Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at $29,000. Transcendent Capital Group LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at $29,000. Finally, True Wealth Design LLC raised its position in Abbott Laboratories by 1,677.8% in the fourth quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock valued at $35,000 after purchasing an additional 302 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Robert B. Ford sold 141,679 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the completion of the transaction, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at $25,617,068.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.10% of the stock is owned by company insiders.

Abbott Laboratories Trading Down 0.4 %

NYSE:ABT opened at $116.40 on Monday. The company has a market cap of $202.49 billion, a PE ratio of 36.26, a P/E/G ratio of 2.90 and a beta of 0.72. The business’s 50 day moving average is $109.24 and its two-hundred day moving average is $108.57. The company has a quick ratio of 1.18, a current ratio of 1.68 and a debt-to-equity ratio of 0.33. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The firm had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.37 billion. During the same quarter in the previous year, the company posted $1.08 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis. On average, analysts predict that Abbott Laboratories will post 4.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Evercore ISI decreased their target price on Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Barclays lifted their price objective on shares of Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Citigroup upped their target price on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Edward Jones lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, July 30th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $125.00 target price on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $121.80.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.